Tri-Drug Artemisinin Therapy for Dengue Bioavailability Limits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no effective treatments or vaccines available for Dengue, a rapidly spreading viral disease caused by the Flaviviridae family of viruses, leading to severe symptoms such as hemorrhagic fever and high mortality rates, with existing Artemisinin Combination Therapies (ACT) being limited by poor bioavailability and potential allergic reactions.
Innovation Solution
A novel TriAct therapy using a combination of three drugs - artemether, artesunate, and berberine - administered through a sublingual spray and oral route, minimizing allergic reactions and enhancing bioavailability, specifically designed for Dengue and other Flaviviridae-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Artemisinin Combination Therapy (ACT) is used to treat Dengue, then some therapeutic effect is achieved, but bioavailability is poor and allergic reactions may occur
Solution Approach 1:
The patent combines three distinct artemisinin derivatives (artemether, artesunate, artemotil) into a composite therapeutic formulation called TriAct therapy. This composite approach leverages the complementary pharmacokinetic and pharmacodynamic properties of each component to achieve improved overall bioavailability and therapeutic reliability while reducing the risk of allergic reactions through drug diversification
2Reliability
If existing Artemisinin Combination Therapy (ACT) is used to treat Dengue, then some therapeutic effect is achieved, but allergic reactions may occur
Solution Approach 1:
The patent applies local quality by selecting specific artemisinin derivatives with different chemical structures and immunogenic profiles. Each derivative in the TriAct combination (artemether, artesunate, artemotil) has distinct properties that reduce cross-reactivity and allergic potential while maintaining therapeutic efficacy, thereby localizing the beneficial effects without the harmful allergic responses
3Ease of operation
If a single drug therapy is used, then treatment is simple, but therapeutic effectiveness against rapidly spreading viral disease is insufficient
Solution Approach 1:
The patent merges three artemisinin derivatives into a single integrated therapeutic regimen (TriAct therapy) that can be administered together. This combining approach maintains operational simplicity for the patient while achieving enhanced therapeutic effectiveness through the synergistic and complementary actions of multiple drugs targeting the viral infection from different mechanisms
Data Source
AI summary
The present invention describes a method of treating individuals suffering from microbial infections, including a viral infection such as Dengue Fever, using an improved Artemisinin Combination Therapy (ACT), known as Tri-ACT. The improved ACT therapy includes administering a combination of three drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is then administered to the individual.